Second Edition of the Pharmaceutical Cannabis Report 2021: with Almirall, Bayer and Novartis, among others – ResearchAndMarkets.com

0


DUBLIN – (COMMERCIAL THREAD) –“The Pharmaceutical Cannabis Report: 2nd Edition” the report was added to ResearchAndMarkets.com offer.

Research on the endocannabinoid system is one of the most promising avenues for new therapies in medicine today. However, regulations are constantly evolving. This report has been compiled to help interested parties understand the Medical Cannabinoid Use market and where it may be heading.

In Europe and the United States, sales of unapproved cannabis products such as smoking and full-spectrum flower oils eclipse those of approved pharmaceuticals. In Europe, however, there is a clear trend towards the use of more precise formulations of unapproved cannabis products as well as pharmaceuticals. In the United States, sales of medical flowers and vaporized products remain dominant among unapproved drugs, but there is also an increase in sales of pharmaceuticals.

Companies mentioned

  • Almirall

  • Bayer

  • C3 Cannabinoid Compounds Company

  • Cronos

  • Ginkgo Bioworks

  • GW Pharmaceuticals

  • Novartis

  • Otsuka

  • PureForm Global

Findings from the Pharmaceutical Cannabis Report: 2nd Edition include:

  • The author estimates that the market size of the three most widely used cannabinoid pharmaceuticals (Epidiolex, Sativex, Dronabinol) would amount to just under 900 million euros in 2021, reaching 1.8 billion euros by 2025.

  • Global surveys of cannabis users indicate that around 40% of consumers have a medical component in their use.

  • Current global expenditure on pain medication around the world is estimated at US $ 63-85 billion annually. However, no cannabinoid has been widely approved for the treatment of pain.

The market sizing section provides forecasts on the estimated sales of the three top-grossing cannabinoid pharmaceuticals – from 2021 to 2025 – including Epidiolex, Sativex, and Dronabinol.

The use of cannabinoids in the treatment of medical conditions offers major opportunities, but also challenges for anyone operating in space. Research on the endocannabinoid system is one of the most promising avenues for new therapies in medicine today. However, regulations are constantly evolving under the feet of operators and their ability to serve patients depends on their ability to navigate a changing governance landscape. This report has been compiled to help interested parties understand the Medical Cannabinoid Use market and where it may be heading.

The majority of medicinal cannabis is currently prescribed in a medically non-traditional manner, with short patient-doctor interactions and a rough dosage of the active pharmaceutical ingredients (eg, by inhaling burnt flowers). In Europe and the United States (US), sales of unapproved cannabis products such as smoked flowers and full spectrum oils eclipse those of approved pharmaceuticals like Epidiolex, Marinol, Sativex, and Cesamet. who were guided by the traditional approval process. In Europe, however, there is a clear trend towards the use of more precise formulations of unapproved cannabis products as well as approved pharmaceuticals. In the United States, sales of medical flowers and vaporized products remain dominant among unapproved drugs, but there is also an increase in sales of pharmaceuticals, primarily Epidiolex.

Epidiolex is currently the star child of a successful cannabinoid pharmaceutical; generating over 430 million euros in sales in 2020 and serving an estimated patient population of over 20,000. The story of GW Pharmaceuticals, the producers of Epidiolex, is instructive regarding the challenges and opportunities of ” operate in the pharmaceutical cannabis space; take more than 20 years to generate significant sales and face several setbacks in clinical trials. The fruits of GW’s strategy are evident, however, with rapid sales growth and the recent acquisition of the company by Jazz Pharmaceuticals for more than 6 billion euros.

Today’s medical cannabis market is bursting with innovation. The author has identified at least 30 late-stage clinical trials using cannabinoid therapies, each of which could have a significant impact on the medicinal cannabis space. Products with new routes of administration, such as metered-dose inhalers and transdermal products, are currently under approval. Research and development on minor cannabinoids such as Cannabigerol (CBG) and Cannabichromene (CBC) is only just beginning, with a lot of therapeutic promise but still with a lack of hard evidence.

Many players in the field of medical cannabis are developing patent portfolios to protect products and their production methods. The industry has yet to see a massive amount of litigation, but that could change soon, as the case between GW Pharmaceuticals and Canopy Growth over proprietary methods of cannabinoid extraction shows. In the area of ​​patents, the imminent expiration of the commercial exclusivity of Epidiolex could soon provide opportunities for potential generics producers to offer cheaper alternatives to patients with rare forms of epilepsy.

Overall, the full potential for the use of medical cannabinoids in the pharmaceutical space has hardly been scratched. In the medium to long term, the publisher expects to see the development of a range of new cannabinoid therapies approved around the world. Space operators can expect these products to gradually gain a larger market share away from unapproved flower and full-spectrum oils over the next 10 years. This will coincide with the liberalization of cannabis for adult use in North America and Europe, which will further distill the use of medicinal products from the flower to more precise formulations.

For more information on this report, visit https://www.researchandmarkets.com/r/v1reck


Share.

Comments are closed.